Tag: DLBCL

Front-Line Treatment of DLBCL – NewsBreak

Dr. Lenz on the Rationale for the CheckMate 9X8 in Metastatic CRC Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer. Heinz-Josef Lenz, MD, FACP, associate director, Clinical Research, J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director, University of Southern…

Continue Reading Front-Line Treatment of DLBCL – NewsBreak

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin’s lymphoma in the United States, with approximately 40% of first-line DLBCL chemoimmunotherapy attempts failing. The FDA approved a new type of antibody-drug conjugate (ADC), Zynlonta (loncastuximab tesirine), once called ADCT-402, on April 23, 2021, for relapsed or…

Continue Reading Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

A Clinical and Immunohistochemical Study

Diffuse large B cell lymphoma is the most common type of lymphoma in Egypt with an unfavorable prognosis. The tumor microenvironment is rich in immune response either T cells or macrophages. The current study is aimed at testing CD4, CD8, CD68, and MMP9 immunohistochemistry of DLBCL activities with the prognosis…

Continue Reading A Clinical and Immunohistochemical Study

FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Officials with the FDA have granted both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation to C-CAR039, a novel autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients…

Continue Reading FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

Stream episode Is CAR-T Therapy Superior to ASCT for Relapsed/Refractory DLBCL? by Healthcare Unfiltered podcast

published on 2022-01-11T11:58:44Z Continuing his ASH Annual Meeting coverage, Chadi invites Matt Maurer (@MaurerStats), MS, principal biostatistician, Mayo Clinic, and Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), to review the three prominent CAR-T studies in relapsed/refractory DLBCL presented at the meeting. Why…

Continue Reading Stream episode Is CAR-T Therapy Superior to ASCT for Relapsed/Refractory DLBCL? by Healthcare Unfiltered podcast

Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis after frontline immunochemotherapy. This retrospective study investigated the effect of consolidative radiation after systemic treatment in newly diagnosed stage I-II de novo CD5+ DLBCL. In this study, 22 patients received consolidative radiotherapy (RT) after immunochemotherapy (chemotherapy + RT…

Continue Reading Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation

Brem Looks at Multiple Treatments for Patients With DLBCL

During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma. Targeted Oncology™: What therapeutic options would you consider at…

Continue Reading Brem Looks at Multiple Treatments for Patients With DLBCL

Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

DISCUSSION QUESTIONS Do you foresee any barriers to using loncastuximab tesirine (Zynlonta) in diffuse large B-cell lymphoma (DLBCL)?​ If loncastuximab were covered by insurance, would you use it in the second line for patients who decline transplant?​ DEVA NATHAN, MD: I have different question. Are you willing to replace R-CHOP [rituximab…

Continue Reading Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Introduction Rituximab (Rituxan; Genentech) is a chimeric anti-CD20 monoclonal antibody widely used in non-Hodgkin lymphoma (NHL) treatment.1 Worldwide, rituximab is recommended for a variety of B-cell malignancies,1,2 and it has a well-established efficacy and safety profile, with more than 4 million patients treated.1,3 In the United States, rituximab is approved…

Continue Reading Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

The Future of Targeted Therapies in DLBCL

In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies. While rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective therapy for diffuse large B-cell lymphoma (DLBCL). However, major unmet clinical needs still exist for patients with…

Continue Reading The Future of Targeted Therapies in DLBCL

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

doi.org/10.1016/j.lrr.2021.100284Get rights and content Abstract In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to…

Continue Reading Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

MRD Surveillance in DLBCL – Capsule Summary Slidesets – Lymphomas and CLL – 2021 ASH Annual Meeting – Oncology

December 11-14, 2021; Atlanta, Georgia Results of this study showed that substantial proportions of clinical relapses were radiographically detected in asymptomatic patients, whereas immunosequencing MRD monitoring demonstrated suboptimal sensitivity. Format: Microsoft PowerPoint (.ppt) File Size: 484 KB Released: December 16, 2021 …

Continue Reading MRD Surveillance in DLBCL – Capsule Summary Slidesets – Lymphomas and CLL – 2021 ASH Annual Meeting – Oncology

MSK Chief of the Lymphoma Service Gilles Sall

December 14, 2021, NEW YORK, NY – A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a…

Continue Reading MSK Chief of the Lymphoma Service Gilles Sall

Promising new treatment for patients with diffuse large B-cell lymphoma

Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin,…

Continue Reading Promising new treatment for patients with diffuse large B-cell lymphoma

Fate Therapeutics Highlights Positive Durability of

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response…

Continue Reading Fate Therapeutics Highlights Positive Durability of

Should patients with DLBCL refractory to frontline RCHOP (or similar) or relapsing within

New data from ASH-2021 /NEJM ZUMA-7 trial (transformed FL were included in this study) Take home messages: Only 30% of patients who are treated with salvage chemotherapy will attain a complete response. Patients with a CR who proceed to ASCT do as well as patients on CAR-T upfront with good…

Continue Reading Should patients with DLBCL refractory to frontline RCHOP (or similar) or relapsing within

Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety. Real-world data on the use of tisagenlecleucel (Kymriah) showed greater efficacy and a favorable safety profile, according to updated findings from a study of the Center for…

Continue Reading Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Addition of Ibrutinib to R-Mini-Chop for Newly Diagnosed DLBCL Shows Promise in an Elderly Population

Adding ibrutinib (Imbruvica) to rituximab (Rituxan) plus mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone [R-mini-CHOP]) improved progression-free survival (PFS), quality of life (QOL), and function in elderly patients with diffuse large B-cell lymphoma (DLBCL), according to the primary analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study presented the 63rd…

Continue Reading Addition of Ibrutinib to R-Mini-Chop for Newly Diagnosed DLBCL Shows Promise in an Elderly Population

CAR-T therapy trials show promise for earlier use in lymphoma

Cell therapy, a relatively new and expensive treatment for certain blood cancers, might soon dislodge a decades-old standard of care for people with a common type of lymphoma that’s returned after initial drugs fail. Results from two late-stage studies, presented over the weekend at the American Society of Hematology’s annual…

Continue Reading CAR-T therapy trials show promise for earlier use in lymphoma

Vincerx Pharma Presents Data o

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company…

Continue Reading Vincerx Pharma Presents Data o

Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting | Small Molecules

Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting Details Category: Small Molecules Published on Sunday, 12 December 2021 17:15 Hits: 116 CAMBRIDGE, MA, USA I December 11, 2021 I Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage…

Continue Reading Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting | Small Molecules

Ibrutinib Plus R-Mini-CHOP Misses OS End Point but Shows Improved PFS in Newly Diagnosed DLBCL

Ibrutinib plus rituximab and mini-CHOP failed to demonstrate a statistically significant improvement in overall survival at 2 years but led to an improvement in progression-free survival, quality of life, and function in elderly patients with diffuse large B-cell lymphoma. Ibrutinib (Imbruvica) plus rituximab (Rituxan) and mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and…

Continue Reading Ibrutinib Plus R-Mini-CHOP Misses OS End Point but Shows Improved PFS in Newly Diagnosed DLBCL

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Data will be…

Continue Reading Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

Treatment with tafasitamab (Monjuvi) and lenalidomide (Revlimid) provided an overall survival (OS) benefit vs standard options in a population of patients with autologous stem cell transplant (ASCT)–ineligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to findings from an expanded analysis of RE-MIND2 study (NCT04697160) that was presented at the 2021…

Continue Reading Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

Loncastuximab Tesirine Plus Ibrutinib on Relapsed DLBCL Trends Favorable to LOTIS-3 Interim Analysis

A preliminary review of the current phase 2 LOTIS-3 trial (NCT03684694) presented at the 2021 American Society of Hematology (ASH) Annual Meeting revealed promising efficacy and encouraging safety in the combination of ibrutinib (Imbruvica) and loncastuximab tesirine (Zynlonta ) in patients with relapsed/refractory (R/R) disseminated large B-cell lymphoma (DLBCL). These…

Continue Reading Loncastuximab Tesirine Plus Ibrutinib on Relapsed DLBCL Trends Favorable to LOTIS-3 Interim Analysis

DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL 11.12.2021 / 18:00 The issuer is solely responsible for the content of this announcement. MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of…

Continue Reading DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of results from a prespecified interim analysis of the pivotal TRANSFORM study, a global, randomized, multicenter, Phase 3 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, as a second-line treatment in…

Continue Reading Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Prof Brian Hill speaks to ecancer about a study he presented at the ASH 2021 meeting into potentially targetable pathways for CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL). He explains that the purpose of the study was to determine the impact of subtypes of DLBCL on the outcomes…

Continue Reading Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Liso-Cel Yields EFS Benefit as Second-line Therapy in LBCL

The phase 3 TRANSFORM study (NCT03575351) showed that patients with relapsed or refractory large B-cell lymphoma (LBCL) had a clinically meaningful improvement in event-free survival (EFS) compared with the standard of care (SOC) when treated with liscocabtagene maraleucel (liso-cel), according to prespecified interim results that were presented at the 2021…

Continue Reading Liso-Cel Yields EFS Benefit as Second-line Therapy in LBCL

Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab

(RTTNews) – MorphoSys AG (MOR) and Incyte (INCY) announced the additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. The treatments include polatuzumab vedotin plus…

Continue Reading Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab

Loncastuximab Tesirine Plus Ibrutinib in Relapsed DLBCL Trends Favorably at LOTIS-3 Interim Analysis – NewsTVPK

An interim analysis of the ongoing phase 2 LOTIS-3 trial (NCT03684694), which was presented at the 2021 Annual Meeting of the American Society of Hematology (ASH), revealed promising efficacy and encouraging safety with the combination of ibrutinib (Imbruvica) plus loncastuximab thesis (Zynlonta) in patients with recurrent / resistant (R /…

Continue Reading Loncastuximab Tesirine Plus Ibrutinib in Relapsed DLBCL Trends Favorably at LOTIS-3 Interim Analysis – NewsTVPK

Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data

(RTTNews) – MorphoSys AG (MOR) and Incyte (INCY) announced the additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. The treatments include polatuzumab vedotin plus…

Continue Reading Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data

Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

CAMBRIDGE, Mass., December 11, 2021–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today shared preclinical data and the Phase 1/1b trial design for EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, an investigational agent being developed for the…

Continue Reading Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company…

Continue Reading Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The MarketWatch News Department was not involved in the creation of this content. December 11, 2021 (ACCESSWIRE via COMTEX) — – RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies – Results from the retrospective cohort analysis indicate significant overall survival improvement…

Continue Reading MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Liso-cel significantly improves outcomes in second-line DLBCL

December 11, 2021 2 min read Source/Disclosures Published by: Source: Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kamdar reports consultant/advisory or speakers bureau roles with AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Genentech, Karyopharm…

Continue Reading Liso-cel significantly improves outcomes in second-line DLBCL

EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

December 11, 2021 3 min read Source/Disclosures Published by: Source: Locke FL, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kite Pharma sponsored this study. Leslie reports advisory board, consultant or speakers bureau roles with AbbVie, AstraZeneca, BeiGene, Celgene/Bristol Myers…

Continue Reading EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

The combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) prolonged median overall survival (OS) compared with other standard options for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a closely matched expanded analysis of the observational, retrospective RE-MIND2 (NCT04697160) study presented at the…

Continue Reading Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

Loncastuximab Tesirine/Ibrutinib Combination Elicits Encouraging Activity in Relapsed/Refractory DLBCL

Treatment with ibrutinib plus loncastuximab tesirine-lpyl resulted in high objective and complete response rates and an acceptable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from an interim analysis of the phase 1/2 LOTIS-3 trial (NCT03684694) that were presented at the 2021 ASH Annual Meeting…

Continue Reading Loncastuximab Tesirine/Ibrutinib Combination Elicits Encouraging Activity in Relapsed/Refractory DLBCL

Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma

1. Metser, U., Hussey, D. & Murphy, G. Impact of (18)F-FDG PET/CT on the staging and management of follicular lymphoma. Br. J. Radiol. 87, 20140360 (2014). CAS  Article  Google Scholar  2. Freedman, A. & Jacobsen, E. Follicular lymphoma: 2020 update on diagnosis and management. Am. J. Hematol. 95, 316–327 (2020)….

Continue Reading Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma

Double-hit lymphoma: optimizing therapy – Docwire News

This article was originally published here Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):157-163. doi: 10.1182/hematology.2021000247. ABSTRACT Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition that some…

Continue Reading Double-hit lymphoma: optimizing therapy – Docwire News

Chugai Pharmaceutical : Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma

Chugai Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma Polivy plus R-CHP significantly improved outcomes in previously untreated diffuse large B-cell lymphoma (DLBCL) compared to the standard of care for the first time in 20 years Filing…

Continue Reading Chugai Pharmaceutical : Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma

Pola-G-Len Regimen Shows Promise as an Alternative to CAR T Cells in Refractory FL

The combination of obinutuzumab (Gazyva) with polatuzumab vedotin (Polivy) or lenalidomide (Revlimid; Pola-G-Len) achieved high responses in patients with heavily pretreated refractory follicular lymphoma (FL) in a phase 1b/2 clinical trial. “Our findings demonstrated that the regimen of Pola-G-Len was safe and had a high level of activity in relapsed…

Continue Reading Pola-G-Len Regimen Shows Promise as an Alternative to CAR T Cells in Refractory FL

Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment

NEW YORK – Qiagen and Denovo Biopharma said on Thursday that they are collaborating to develop a blood-based companion diagnostic test to identify patients expressing a genomic biomarker who are likely to respond to Denovo’s investigational DB102 treatment for diffuse large B-cell lymphoma. Under the agreement, Qiagen will develop an…

Continue Reading Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment

Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. QIAGEN (NYSE: QGEN) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who…

Continue Reading Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

– QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102 – The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. SAN DIEGO and…

Continue Reading Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Qiagen And Denovo Biopharma Partner To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma

Qiagen And Denovo Biopharma Partner To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma Published: 12/09/2021 14:36 GMT Qiagen NV (QGEN) – Denovo Biopharma and Qiagen Partner to Develop Companion Diagnostic Test for Treatment of Diffuse Large B-cell Lymphoma (dlbcl).Partners Seek FDA Premarket Approval (pma) of Companion…

Continue Reading Qiagen And Denovo Biopharma Partner To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma

Circulating Exosomal MicroRNAs as Diagnostic and Prognostic Biomarkers in Patients with Diffuse Large B-Cell Lymphoma

Background: Exosomal microRNAs (miRNAs) are potential biomarkers for a variety of tumors but have not yet been studied in diffuse large B-cell lymphoma (DLBCL). Here, we investigated the use of exosomal miRNAs in DLBCL diagnosis and prognosis. Methods: A total of 256 individuals, including 133 DLBCL patients, 94 healthy controls…

Continue Reading Circulating Exosomal MicroRNAs as Diagnostic and Prognostic Biomarkers in Patients with Diffuse Large B-Cell Lymphoma

Part 1: Choosing a Third-Line Treatment for Refractory DLBCL

DISCUSSION QUESTION What are the key factors that influence your decision making for third-line therapy? PAOLO CAIMI, MD: What are the key factors that influence your decision in choice of regimen for patients who are in the third-line therapy? Any comments about the things that you use when you’re thinking…

Continue Reading Part 1: Choosing a Third-Line Treatment for Refractory DLBCL

MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)

doi.org/10.1016/j.leukres.2021.106769Get rights and content Highlights • MiR-665 is down-regulated in the serum exosomes from DLBCL patients. • MiR-665 suppresses DLBCL cell proliferation and invasion and induces apoptosis. • LASP1 is a target of miR-665. • MiR-665 regulates DLBCL progression through targeting and inhibiting LASP1. Abstract Diffuse large B cell lymphoma…

Continue Reading MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)

Qiagen, Denovo Biopharma Partner To Develop Companion Diagnostic Test

Published: 12/09/2021 06:38 GMT Qiagen NV (QGEN) – Qiagen and Denovo Biopharma Partner to Develop Companion Diagnostic Test for Treatment of Diffuse Large B-cell Lymphoma (dlbcl).Qiagen’s Blood-based Test Will Help to Identify Patients With Diffuse Large B-cell Lymphoma (dlbcl) Likely to Respond to Denovo’s New Investigational Cancer Treatment Db102tm.Partners Seek…

Continue Reading Qiagen, Denovo Biopharma Partner To Develop Companion Diagnostic Test

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102TM The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. New master collaboration agreement adds…

Continue Reading QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Qiagen, Denovo To Develop Companion Diagnostic Test For Diffuse Large B-Cell Lymphoma Treatment

(RTTNews) – Qiagen (QGEN) and Denovo Biopharma said that they have collaborated to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 who are likely to respond to Denovo’s investigational cancer drug DB102 for treatment of diffuse large B-cell lymphoma or DLBCL, one of the…

Continue Reading Qiagen, Denovo To Develop Companion Diagnostic Test For Diffuse Large B-Cell Lymphoma Treatment

In some lymphomas, ibrutinib yields “almost unheard-of” survival rates

Younger patients with two genetic subtypes of diffuse large B cell lymphoma (DLBCL) – specifically MCD and N1 – show substantial improvements in survival with the addition of ibrutinib to standard R-CHOP chemotherapy, compared with R-CHOP alone, new research shows. The findings, published Nov. 4, 2021, in Cancer Cell, come…

Continue Reading In some lymphomas, ibrutinib yields “almost unheard-of” survival rates

MD Anderson research highlights 9 December

ATLANTA ― The University of Texas MD Anderson Cancer Center‘s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations at the 2021 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches, and novel…

Continue Reading MD Anderson research highlights 9 December

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster presentation featuring data from the company’s ongoing Phase 2 CLOVER-1 study of…

Continue Reading Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

Choosing a Third-Line Treatment for Refractory DLBCL

DISCUSSION QUESTION What are the key factors that influence your decision making for third-line therapy? PAOLO CAIMI, MD: What are the key factors that influence your decision in choice of regimen for patients who are in the third-line therapy? Any comments about the things that you use when you’re thinking about…

Continue Reading Choosing a Third-Line Treatment for Refractory DLBCL

Vincerx Pharma (VINC) Receives Orphan Drug Designation from EC for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s…

Continue Reading Vincerx Pharma (VINC) Receives Orphan Drug Designation from EC for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Vincerx Pharma Receives Orphan Drug Designation from

PALO ALTO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s PTEFb/CDK9 inhibitor, for the…

Continue Reading Vincerx Pharma Receives Orphan Drug Designation from